IPOs and Secondaries
IPOs and Secondaries Articles
ThinkstockLast week may have been something of a disappointment both to investors and companies seeking to launch their initial public offerings, but one sector did just fine. Two special-purpose...
Published:
Last Updated:
The lost children of the Web 2.0 internet IPO surge are Groupon Inc. (NASDAQ: GRPN) and Zynga Inc. (NASDAQ: ZNGA) which never created strong business models. While each stock has fallen this year,...
Published:
ThinkstockWhat was supposed to be the year-to-date’s largest initial public offering went ahead Thursday morning with First Data Corp. (NYSE: FDC) selling 160 million shares at an IPO price of $16...
Published:
Last Updated:
Congatec Holding has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Patriot National updates terms and underwriters for secondary offering valued at up to $80 million.
Published:
Adesto Technologies will offer 6 million shares at an expected price of $7 in and IPO valued up to more than $48 million.
Published:
The underwriters for the SiteOne Landscape Supply IPO are Deutsche Bank, Goldman Sachs and UBS Investment Bank.
Published:
Jack Dorsey's Square Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Appellis Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering.
Published:
SynCardia Systems has withdrawn its filing for an initial public offering, but no reason was offered for the withdrawal.
Published:
Last Updated:
Station Casinos has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Axsome Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Duluth Holdings intends to list its Class B shares on the Nasdaq Global Market under the symbol DLTH.
Published:
Can-Fite BioPharma announced that it has entered into definitive agreements with existing institutional investors in regard to a secondary offering.
Published:
Nabriva Therapeutics entered the market in mid-September, and now the quiet period has passed, allowing the underwriters can make calls.
Published: